A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy

Brief description of study

The purpose of this study is to learn how well an investigational drug patch (DBV712) works and how safe it is compared with a placebo patch in 4 to 7-years-old children with a peanut allergy. DBV712 contains a small amount of peanut protein and is designed to potentially desensitize (or make less sensitive) a peanut-allergic person by repeated exposures to very small amounts of peanut via the skin. The objective of the study drug patch is to reduce the risk of allergic reactions and additionally minimize the severity of allergic reactions if a peanut-allergic person is accidentally exposed to peanuts. This study will last about 58 weeks. You and your child will be asked to attend at least 12 in-person study visits and 5 phone calls with a study team member over this period.


Clinical Study Identifier: s23-00262
Principal Investigator: Anna H Nowak-Wegrzyn.
Other Investigator: Kanwaljit Brar.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.